Page 48 - 南京医科大学学报自然科学版
P. 48

第
                                                                                                  第40卷第6期41卷第3期
               ·354 ·                            南 京    医 科 大 学 学         报                        2020年6月年3月
                                                                                                   2021

                   against glypican ⁃ 3 in hepatocellular carcinoma[J]. J  [J]. 南京医科大学学报(自然科学版),2015,35(3):
                   Transl Med,2020,18(1):295                         393-397
             [6] XU C,YAN Z,ZHOU L,et al. A comparison of glypican⁃  [12] DAN L,NAN L,ZHANG Y F,et al. Persistent polyfunc⁃
                   3 with alpha⁃fetoprotein as a serum marker for hepatocel⁃  tional chimeric antigen receptor T cells that target glypi⁃
                   lular carcinoma:a meta⁃analysis[J]. J Cancer Res Clin  can 3 eliminate orthotopic hepatocellular carcinomas in
                   Oncol,2013,139(8):1417-1424                       mice[J]. Gastroenterology,2020,158(8):2250-2265.e20
             [7] LIU S,WANG M,ZHENG C,et al. Diagnostic value of se⁃  [13] GAO H,LI K,TU H,et al. Development of T cells redi⁃
                   rum glypican⁃3 alone and in combination with AFP as an  rected to glypican ⁃ 3 for the treatment of hepatocellular
                   aid in the diagnosis of liver cancer[J]. Clin Biochem,  carcinoma[J]. Clin Cancer Res,2014,20(24):6418-
                   2020,79(19):54-60                                 6428
             [8] NISHIDA T,KATAOKA H. Glypican 3⁃targeted therapy  [14] LI N,WEI L,LIU X,et al. A Frizzled⁃like cysteine⁃rich
                   in hepatocellular carcinoma[J]. Cancers(Basel),2019,  domain in glypican⁃3 mediates Wnt binding and regulates
                   11(9):1339                                        hepatocellular carcinoma tumor growth in mice[J]. Hepa⁃
             [9] ZHOU A ,AMIN M ,FOWLER K J ,et al. Complete         tology,2019,70(4):1231-1245
                   response to erlotinib and bevacizumab in a patient with  [15] HU P,KE C,GUO X,et al. Both glypican ⁃ 3/Wnt/β ⁃
                   biphenotypic(hepatobiliary)primary liver carcinoma[J].  catenin signaling pathway and autophagy contributed to
                   J Natl Compr Canc Netw,2015,13(12):1468-1473      the inhibitory effect of curcumin on hepatocellular carci⁃
             [10] SHI D,SHI Y,KASEB A O,et al. Chimeric antigen recep⁃  noma[J]. Dig Liver Dis,2019,51(1):120-126
                   tor⁃glypican⁃3 T⁃cell therapy for advanced hepatocellular  [16] WU Y,LIU H,WENG H,et al. Glypican⁃3 promotes epi⁃
                   carcinoma:results of phase I trials[J]. Clin Cancer Res,  thelial⁃mesenchymal transition of hepatocellular carcino⁃
                   2020,26(15):3979-3989                             ma cells through ERK signaling pathway[J]. Int J Oncol,
             [11] 曹风华,汪顺才,马        洁,等. 血清中磷酯酰肌醇蛋白聚                  2015,46(3):1275-1285
                   糖⁃3 及高尔基体蛋白⁃73 异常表达对肝癌的诊断价值                                            [收稿日期] 2020-05-13










                                                                                                 

















                              欢迎关注我刊微博、微信公众号!






                              
   43   44   45   46   47   48   49   50   51   52   53